|
Administration
Should be taken on an empty stomach. Take 15-30 min before meals.
|
|
Contraindications
Prolactin-releasing pituitary tumour (prolactinoma), conditions where stimulation of gastric motility may be harmful (e.g. gastrointestinal haemorrhage, mechanical obstruction or perforation), known existing prolongation of cardiac conduction intervals (particularly QTc), underlying cardiac disease (e.g. CHF), significant electrolyte disturbances (e.g. hypokalaemia, hypomagnesaemia, hyperkalaemia). Moderate or severe hepatic impairment. Concomitant use with QT-prolonging drugs or potent CYP3A4 inhibitors (e.g. azole antifungals, macrolides, protease inhibitors, nefazodone).
|
|
Special Precautions
Patient with personal or family history of breast cancer, risk factors for sudden cardiac arrest (e.g. family history of coronary artery disease, high blood pressure, obesity, hypercholesterolaemia, diabetes, alcoholism, smoking). Renal and mild hepatic impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Monitor renal function. Obtain ECG at baseline then periodically during treatment.
|
|
Adverse Reactions
Significant: Increased prolactin levels (dose-dependent). Very rarely, QT prolongation.
Eye disorders: Oculogyric crisis.
Gastrointestinal disorders: Dry mouth, diarrhoea.
General disorders and administration site conditions: Asthenia.
Immune system disorders: Very rarely, anaphylactic reaction (including anaphylactic shock).
Investigations: Very rarely, abnormal LFT.
Nervous system disorders: Headache, somnolence. Very rarely, convulsion, extrapyramidal disorder.
Psychiatric disorders: Anxiety, loss of libido. Very rarely, agitation, nervousness.
Renal and urinary disorders: Very rarely, urinary retention.
Reproductive system and breast disorders: Breast pain and tenderness, galactorrhoea. Rarely, amenorrhoea, gynaecomastia.
Skin and subcutaneous tissue disorders: Rash, pruritus. Very rarely, angioedema, urticaria.
Potentially Fatal: Very rarely, ventricular arrhythmias, Torsade de Pointes, sudden cardiac death. |
|
Drug Interactions
Decreased bioavailability with antacids or antisecretory agents; avoid concurrent use. Anticholinergic agents (e.g. dextromethorphan, diphenhydramine) may antagonise the anti-dyspeptic effect of domperidone.
|
|
CIMS Class
|
|
ATC Classification
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
|
Sign Out
